- Home
- RXST vs GYRE Comparison
RXST vs GYRE Comparison
Compare RXST & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXST
- GYRE
- Stock Information
- Founded
- RXST 1997
- GYRE 2002
- Country
- RXST United States
- GYRE United States
- Employees
- RXST N/A
- GYRE N/A
- Industry
- RXST Biotechnology: Electromedical & Electrotherapeutic Apparatus
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- RXST Health Care
- GYRE Health Care
- Exchange
- RXST Nasdaq
- GYRE Nasdaq
- Market Cap
- RXST 1.0B
- GYRE 990.4M
- IPO Year
- RXST 2021
- GYRE N/A
- Fundamental
- Price
- RXST $14.43
- GYRE $8.88
- Analyst Decision
- RXST Buy
- GYRE
- Analyst Count
- RXST 10
- GYRE 0
- Target Price
- RXST $38.50
- GYRE N/A
- AVG Volume (30 Days)
- RXST 1.2M
- GYRE 209.4K
- Earning Date
- RXST 05-07-2025
- GYRE 05-19-2025
- Dividend Yield
- RXST N/A
- GYRE N/A
- EPS Growth
- RXST N/A
- GYRE N/A
- EPS
- RXST N/A
- GYRE 0.05
- Revenue
- RXST $139,927,000.00
- GYRE $105,757,000.00
- Revenue This Year
- RXST $24.34
- GYRE $22.01
- Revenue Next Year
- RXST $21.83
- GYRE $88.14
- P/E Ratio
- RXST N/A
- GYRE $184.70
- Revenue Growth
- RXST 57.09
- GYRE N/A
- 52 Week Low
- RXST $13.50
- GYRE $6.11
- 52 Week High
- RXST $66.54
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- RXST 25.56
- GYRE 51.54
- Support Level
- RXST $13.79
- GYRE $7.03
- Resistance Level
- RXST $14.93
- GYRE $8.44
- Average True Range (ATR)
- RXST 1.34
- GYRE 1.12
- MACD
- RXST -0.29
- GYRE 0.23
- Stochastic Oscillator
- RXST 9.78
- GYRE 92.33
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.